Immunovaccine pairs with security firm Leidos on Zika work

Downtown Halifax, Nova Scotia, as seen from the Dartmouth waterfront
Downtown Halifax

Nova Scotia's Immunovaccine has teamed with national security contractor Leidos for Zika vaccine research in an approach that the pair hopes can expedite vaccine development during rapid disease outbreaks.

Through the deal, Leidos will handle antigen discovery with its Virtual Pharmaceutical Development Program, while Immunovaccine will formulate promising candidates in its DepoVax adjuvanting delivery platform. After the team identifies candidates, the pair will conduct animal studies in conjunction with Dr. Gary Kobinger of Canada's National Microbiology Laboratory.

Immunovaccine CEO Frederic Ors noted in an interview that Kobinger, a noted Ebola scientist, is "always working on emerging viruses in the world," and has animal models the team will benefit from. "This is going to be very useful when we are ready because this is going to speed up the entire process," he said.


Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

The team hopes the model will be replicable to improve on the current speed of vaccine development in the face of fast-moving outbreaks. The pairing comes as numerous companies race to create vaccines and as Zika has reportedly spread in 50 countries and territories worldwide. WHO has said that 18 companies and organizations are working on vaccines.

As with Ebola, some experts have voiced frustration with the scramble to create vaccines following the identification of an epidemic, leaving communities vulnerable to disease.

At a White House briefing this week, NIAID Director Anthony Fauci reported that the first Zika vaccine candidate is on track to enter clinical trials in September. During that event, U.S. health officials warned that Zika is "scarier" than initially thought, with the mosquitoes that spread the virus in 30 states.

The officials are pressing Congress to pass about $1.9 billion in emergency Zika funding or work in other disease areas will be tabled.

- here's the Immunovaccine release
- get more from Reuters


Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.